APPLICATION OF MULTI-CRITERIA DECISION ANALYSIS TO DETERMINE THE VALUE OF PROPHYLAXIS RELATIVE TO ON-DEMAND TREATMENT IN HAEMOPHILIA A AND EMICIZUMAB VERSUS REPLACEMENT THERAPY IN THE GREEK HEALTHCARE SETTING

被引：0
|
作者：
Gourzoulidis, G. [1 ,2 ]
Stefanou, G. [2 ]
Economou, M. [3 ]
Vakalopoulou, S. [4 ]
Filippidis, G. [5 ]
Soultatis, G. [6 ]
Kontos, D. [7 ]
Tzima, S. [8 ]
Ntemousis, F. [8 ]
Fassa, A. [8 ]
Kourlaba, G. [2 ]
机构：
[1] Univ West Attica, Sch Publ Hlth, Dept Publ Hlth Policy, Athens, Greece
[2] ECONCARE LP, Athens, Greece
[3] Aristotle Univ Thessaloniki, Hippocratio Hosp, Pediat Dept 1, Thessaloniki, Greece
[4] Aristotle Univ Thessaloniki, Hippokrat Gen Hosp Thessaloniki, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[5] Greek Haemophilia Soc, Athens, Greece
[6] Laikon Gen Hosp, Athens, Greece
[7] Panhellen Pharmaceut Assoc, Athens, Greece
[8] Roche Hellas SA, Athens, Greece
来源：
HAEMOPHILIA | 2021年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ABS050
引用
收藏
页码：45 / 45
页数：1
相关论文
共 11 条
  • [1] Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting
    George Gourzoulidis
    Garyfallia Stefanou
    Marina Economou
    Sofia Vakalopoulou
    George Filippidis
    George Soultatis
    Dimitrios Kontos
    Sotiria Tzima
    Fotis Ntemousis
    Angeliki Fassa
    Georgia Kourlaba
    Clinical Drug Investigation, 2022, 42 : 75 - 85
  • [2] Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting
    Gourzoulidis, George
    Stefanou, Garyfallia
    Economou, Marina
    Vakalopoulou, Sofia
    Filippidis, George
    Soultatis, George
    Kontos, Dimitrios
    Tzima, Sotiria
    Ntemousis, Fotis
    Fassa, Angeliki
    Kourlaba, Georgia
    CLINICAL DRUG INVESTIGATION, 2022, 42 (01) : 75 - 85
  • [3] Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
    Teresa Alvarez-Roman, Maria
    Cuervo-Arango, Ignacio
    Perez-Santamarina, Rafael
    Luis Poveda, Jose
    Antonio Romero, Jose
    Santamaria, Amparo
    Luis Trillo-Mata, Jose
    Tort, Marina
    Badia, Xavier
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2019, 2019 : 1 - 8
  • [4] DETERMINING THE VALUE OF EMICIZUMAB (HEMLIBRA®) FOR THE PROPHYLAXIS TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
    Alvarez, M. T.
    Cuervo-Arango, I
    Perez-Santamarina, R.
    Poveda, J.
    Romero, J. A.
    Santamaria, A.
    Trillo, J. L.
    Tort, M.
    Badia, X.
    VALUE IN HEALTH, 2018, 21 : S462 - S463
  • [5] DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
    Alvarez, E.
    Alvarez, M. T.
    Cuervo-Arango, I
    Nunez, R.
    Perez-Santamarina, R.
    Poveda, J. L.
    Romero, J. A.
    Queralt, M.
    Pablo, Q.
    Luis, V
    Tort, M.
    Badia, F. J.
    VALUE IN HEALTH, 2019, 22 : S860 - S860
  • [6] Application of a Value Framework to Determine the Value of Prophylaxis Versus On-Demand Treatment in Adults with Hemophilia A in China
    Baoying Tan
    Ailing Lin
    Rong Han
    Lu Bai
    Jing Sun
    Shanlian Hu
    Jianwei Xuan
    Advances in Therapy, 2025, 42 (4) : 1881 - 1891
  • [7] APPLICATION OF MULTI-CRITERIA DECISION ANALYSIS (MCDA) TO DETERMINE THE VALUE OF TREATMENTS FOR THE MODERATE TO SEVERE PLAQUE PSORIASIS IN SPAIN
    Badia, X.
    de la Cueva, P.
    Rodriguez Moreda, F.
    Trillo, J. L.
    Guarga, L.
    VALUE IN HEALTH, 2017, 20 (09) : A564 - A564
  • [8] Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi-criteria decision analysis
    Garcia-Diego, Daniel-Anibal
    Badia, Xavier
    Benitez-Hidalgo, Olga
    Jimenez, Victor
    Juarez, Juan Carlos
    Nunez, Ramiro
    Poveda, Jose Luis
    Trillo, Jose Luis
    Valles, Joan-Antoni
    HAEMOPHILIA, 2024,
  • [9] A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients
    Jamal, Munirah
    Sathar, Jameela
    Jamari, Jamaliah
    Saffian, Shamin Mohd
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2023, 30 (01): : 129 - 136
  • [10] VALUE CONTRIBUTION OF OLIPUDASE ALFA THERAPY FOR THE TREATMENT OF NON-CENTRAL NERVOUS SYSTEM MANIFESTATIONS OF ACID SPHINGOMYELINASE DEFICIENCY (ASMD) BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
    Abad, M. R.
    Gonzalez-Meneses, A.
    Gras, E.
    Poveda, J. L.
    Trillo, J. L.
    de Vicente, D.
    Villarubia, J.
    Baret, M.
    Badia, X.
    VALUE IN HEALTH, 2022, 25 (12) : S321 - S322
12